Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
Open Access
- 15 December 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32573
Abstract
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.Keywords
This publication has 10 references indexed in Scilit:
- Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort StudyAmerican Journal of Kidney Diseases, 2020
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort studyCanadian Medical Association Journal, 2020
- Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled TrialDrugs, 2020
- SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic reviewWorld Journal of Diabetes, 2019
- Acute renal outcomes with sodium‐glucose co‐transporter‐2 inhibitors: Real‐world data analysisDiabetes, Obesity and Metabolism, 2018
- Serum uric acid and acute kidney injury: A mini reviewJournal of Advanced Research, 2017
- Acute kidney injury from SGLT2 inhibitors: potential mechanismsNature Reviews Nephrology, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Fructose and uric acid in diabetic nephropathyDiabetologia, 2015
- Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the ratKidney International, 1998